11
TNFi IL-17i IL-12/23i, IL-23i JAKi PDE4i
— — — Caution —
Avoid — — — —
— — — Caution —
— — — — —
— — — — —
Caution Caution Caution Caution Caution
Caution Caution Caution Caution Caution
Caution Caution Caution Caution Caution
Caution Caution Caution Caution Caution
Avoid — — — —
— — — — Caution
Abbreviations
bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD (MTX, SSZ,
LEF, CsA; unless otherwise specified); CsA, ciclosporin; CTLA4-Ig, CTLA4-immunoglobulin
fusion protein; CVD, cardiovascular disease; DMARD, disease-modifying antirheumatic drugs;
ETN, etanercept; GC, glucocorticoids; GRAPPA, Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis; IA, intra-articular; IBD, inflammatory bowel disease;
IL-12/23i, IL-12/23 inhibitor; IL-17i, IL-17 inhibitor; IL-23i, IL-23 inhibitor; JAK,
Janus kinase; JAKi, Janus kinase inhibitor; LEF, leflunomide; MS, multiple sclerosis; MTX,
methotrexate; NSAIDS, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase
4; PDE4i, phosphodiesterase 4 inhibitor (apremilast); PRP, patient research partners; PsA,
psoriatic arthritis; SIJ, sacroiliac joint; SSZ, sulfasalazine; TNFi, TNF inhibitor; UC, ulcerative
colitis; VTE, venous thromboembolism
